Development of antibody-drug conjugates (ADCs) represents a significant step forward and several agents targeting ZIP6 show promise; ladiratuzumab vedotin (SGN-LIV1A) is in clinical trials for metastatic breast cancer (231) and BRY812 targets colorectal cancer in preclinical models (169), validating ZIP6 as a promising therapeutic target in a range of cancers. This evidence concerns the gene SLC39A6 and cancer.